Relmada Therapeutics (RLMD) EPS (Weighted Average and Diluted) (2014 - 2026)
Relmada Therapeutics (RLMD) reported EPS (Weighted Average and Diluted) of -$0.22 for Q1 2026, up 62.07% year-over-year from -$0.14 in Q1 2025, and up 24.14% quarter-over-quarter from -$0.29 in Q4 2025.
Relmada Therapeutics (RLMD) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 11 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.22 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.22, up 62.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.11 (up 55.78% YoY), and the FY2025 annual result was -$1.45, up 45.28% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.22 in Q1 2026 per RLMD's latest filing, from -$0.29 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.22 in Q1 2026 and troughed at -$1.35 in Q1 2022.
- A 5-year average of -$0.76 and a median of -$0.72 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2026: EPS (Weighted Average and Diluted) grew 0.23% in 2022, then jumped 62.07% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.26 in 2022, then jumped by 34.13% to -$0.83 in 2023, then grew by 25.3% to -$0.62 in 2024, then surged by 53.23% to -$0.29 in 2025, then advanced by 24.14% to -$0.22 in 2026.
- Business Quant data shows RLMD's EPS (Weighted Average and Diluted) at -$0.22 in Q1 2026, -$0.29 in Q4 2025, and -$0.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.22 |
| Dec 31, 2025 | -0.29 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.30 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -0.62 |
| Sep 30, 2024 | -0.72 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.72 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.73 |
| Jun 30, 2023 | -0.84 |
| Mar 31, 2023 | -0.87 |
| Dec 31, 2022 | -1.26 |
| Sep 30, 2022 | -1.31 |
| Jun 30, 2022 | -1.33 |
| Mar 31, 2022 | -1.35 |
| Dec 31, 2021 | -1.80 |
| Sep 30, 2021 | -2.44 |
| Jun 30, 2021 | -1.56 |